C4 Therapeutics (CCCC) Insider Steven Hoerter Buys 62,000 Shares

Steven Hoerter bought 62,000 shares of C4 Therapeutics, Inc. (NasdaqGS: CCCC) on June 24, 2026. The transaction had a reported value of $0, as it was not disclosed at a specific price. This purchase comes as the stock trades at $4.40, close to its 52-week high of $5.17.

Inside Steven Hoerter's Trade

Hoerter's acquisition of 62,000 shares signifies a potential commitment to the company's future. This purchase marks his first reported insider transaction in this position.

Other Institutional Activity in C4 Therapeutics

Several other institutional players have also adjusted their positions in C4 Therapeutics. Morgan Stanley trimmed its holdings by 205,036 shares, leaving it with 8,867,338 shares valued at about $24.7 million. Blackrock Inc. increased its stake significantly by 5,848,177 shares, now holding 7,896,718 shares worth roughly $21.99 million. Meanwhile, Squadron Capital Management LLC raised its share count by 4,950,000 shares, totaling 7,200,000 shares with a value of about $20.1 million.

C4 Therapeutics, Inc. Stock Up 29.8%

C4 Therapeutics is currently trading at $4.40, which positions it near its 52-week high of $5.17. This growth follows a period of stronger performance after dipping to a low of $1.69 over the last year. The stock's volatility is reflected in its beta of 2.945, indicating greater risk compared to the overall market.

Recent Earnings

C4 Therapeutics reported revenue of $35.04 million, reflecting a growth rate of 2.8%. However, the company has a negative net margin of about -2.89% and an EPS of -$0.91. The next earnings date is set for November 5, 2026.

Analysts Set New Price Targets

On October 9, 2026, JP Morgan initiated coverage of C4 Therapeutics with an Overweight rating and a price target of $10. Currently, analysts have a mean price target of $13.33, based on six opinions collected.

About C4 Therapeutics

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, MA. It focuses on developing innovative therapies to degrade proteins that cause diseases. Its leading candidate is Cemsidomide, aimed at treating multiple myeloma, which has successfully completed its phase 1 trials.

Bottom Line

Investors will watch for the upcoming earnings report on November 5, 2026, as it could provide insights into C4 Therapeutics' performance and future outlook. The recent insider buying underscores confidence in the company's direction, despite the current volatility in the biotech sector.